Skip to main content
LIVN $92.64 +0.22%
LIVN logo
LIVN · LivaNova PLC
Track LIVN — free
Market Cap
$5.09B
Shares
55.09M
Volume · Nov 17 87.86K Avg daily vol (3M) 670.55K
All webcasts

Conference · 2026-11-10

LivaNova PLC (LIVN) November 10, 2026 Conference Transcript

Concluded Nov 10, 2026 Audio replay
Nov 10, 2026 31:32 42 turns
Period
2026-11-10
Runtime
31:32
Sources
2 artifacts

Transcript & audio

31:32 Audio
Mike Pollark Analyst — Wolf Research, LLC

Good morning. Welcome to day two of the Wolf Healthcare Conference. My name is Mike Pollark, Medical Device Analyst here at Wolf Research. Pleased in this session to be joined by Lee Vinova. From the company, we have CEO Vlad Makatsaria and Chief Innovation Officer Ahmet Tezel. Vlad and Ahmet, good to be with you. Thanks for being here.

Well, good morning, and Mike and everybody, good morning, and thank you for the opportunity to join you this morning.

Mike Pollark Analyst — Wolf Research, LLC

Maybe, Vlad, I'll just pass it to you to start to set the stage, kind of reflections on 2026 so far, highlights, challenges to the extent they're worth mentioning, and, you know. Top few priorities as you roll into 27. What are you most focused on for the company across the divisions?

Thank you for the question. So I'm going to assume most of you kind of know the living of a story, but if you don't, we have two businesses that are leaders in their markets. So one is epilepsy, and it's treatment of drug-resistant epilepsy with neuromodulation, and then the other side of the business. It's a cardiopulmonary business, so it's perfusion during open-heart surgery, surgical procedure. So both of these businesses are leaders in their space. We are in the process of launching obstructive sleep apnea business with proximal hypoglossal nerve stimulation, so that is on track for the launch next year. And then we have a... Optionality, upside optionality with our difficult to treat depression business that is also hypoglossal nerve stimulation, so neuromodulation based business. And, you know, one thing that kind of I'm really pleased with the progress this year is with the quality of our growth. So we have delivered now several, actually three years of double-digit growth, but what I'm really pleased with this year is this growth is very balanced. So it's balanced between neuromodulation or epilepsy site and cardiopulmonary. Both businesses are growing double-digit. I'm pleased with our performance across various regions around the world, US, Europe, Asia-Pacific, Latin America, so it's well-balanced geographically, and even within businesses, like, for example, in cardiopulmonary. Our growth historically has been dominated by heart-lung machines. Now you see a much more balanced growth between heart-lung machines and oxygenators. On the epilepsy front, the growth is driven both by price, volume, by new patients, by replacements. So that kind of quality of growth and well-balanced growth gives us more confidence in the sustainability of that growth moving forward. And, you know, as we... And to 2027, the focus remains kind of consistent as, you know, one is on building a strong team, focusing on our culture. So that's number one. Make sure that the growth is at the forefront of everything we do and continue driving growth. Innovation agenda, oxygen for our future, and making sure that both in the core businesses but also our new categories that we are executing well versus our plans on innovation front and that culture of innovation is thriving. And then finally, execution is to make sure that You know, we do everything efficiently, and we continue to generate strong operating margins and cash.

Mike Pollark Analyst — Wolf Research, LLC

Good setting of the stage. Thank you, Vlad. So let's go cardiopulmonary to start. We'll do epilepsy, and then we'll get into sleep apnea and maybe a quick question on depression at the end. So cardiopulmonary, I'll ask it through the lens of into 27, I think. Like, Essence. It goes from 80% of shipments this year to probably 100%. That's an embedded revenue growth tailwind on mix. Oxygenators, you've just announced a new completion of, I believe, major manufacturing expansion. It provides volume tailwinds for the consumable side, and maybe even heater-cooler and air-manager, those modules will start rolling out at some point next year. If I characterize the drivers correct, and which of those, incrementally relative to the last few years of really good cardiopulmonary growth, is even more impactful next year?

So maybe I'll start with the growth drivers, and then I'll turn it over to Amit to talk a bit more about the innovation and the roadmap ahead of us. Thank you. So in the cardiopulmonary, you characterize the growth drivers very well. I would add maybe one moist price to that, but maybe start with oxygenators. So in cardiopulmonary, about one-third of our business is equipment-based. It's heart-lung machines. About two-thirds of the business are disposables, and within disposables, oxygenators. Are the most differentiated and meaningful part of the portfolio. So, in Oxygenators, we kind of, it's a mature market, but we were able to gain about 10 points of share in the last couple of years. So, we went from 30 to 40 percent, and we have strong confidence in our ability to continue growing that market share driven by kind of three things. You know, one is commercial excellence, two is our ability to supply better, and three, innovation, which Ahmet will talk about. On the supply, supply has been the key driver. And the reason for that is that the procedures themselves went from low single-digit growth to mid-single-digit growth over the past few years. And we see that that mid-single-digit growth is sustainable moving forward, given the demographics, dynamics, and also some of the patients that used to have minimally invasive procedures are now coming back for more advanced. type of surgery. And that really drove the fact that the demand for the oxygenators is higher than the market's ability to supply. We've been focused significantly on significantly improving our outputs on manufacturing. And the last two kind of big milestones was our... Long-term partnership with Thermo Fisher in terms of supply agreement of a key component for oxygenators that kind of removes that as a barrier moving forward. But also we, in October, specifically, we opened a new manufacturing line in our own facility for oxygenators. And that manufacturing line, you know, Gives us an opportunity to continue with double-digit output growth into 2027. So that's that's oxygenators. On heart-lung machines, so again, we launched a new heart-lung machine a couple of years ago, and we've been gradually upgrading our fleet into this new machine called Essence. Last year 80% of this year 80% of all Heartland machines we placed were new ones or essence ones. Next year, 100% of our placements will be essence. But if you look at the broader market, you know, we have 70% market share approximately in heartland machines. That translates in about 10,000 units placed out there. And only about 20% of those units today are essence. So it gives us still a significant lean runway, and maybe we won't get that price mix impact after 2027. We can still play on volume growth as we have the significant opportunity to upgrade the remaining fleet of equipment. And then you talked a little bit about heater cooler and air manager. So those are modules into the hard line machines. We launched that new essence machine with an old modules. So we are due to upgrade those. And as of next year, we will start getting regulatory approvals for air manager and heater cooler. It will start in Europe, and then it will kind of gradually expand in other parts of the world. But the more meaningful... Growth will come in 2028, and maybe Ahmed, maybe comment on innovation.

Ahmet Tezel Other

Yeah, I mean, we're excited about three main pieces that Vlad talked about. The oxygenator launch that will happen in 2028. We're really excited about it because out of the 10 parameters that perfusionists care about in the performance of an oxygenator, this will become the best in class in all 10. So we already have that kind of share momentum happening. We believe it will just fuel it. It's a highly differentiated oxygenator. It will not compete in terms of capacity with the existing oxygenator because it's in a different part of the plant in Italy. So we also like that fact. And I would think of like the air manager and heater cooler, like if Essence was a performance car, which it is, these will be like the tires or the gasoline that you put in. It just elevates the performance of Essence because they are allowing Essence to perform at its peak capacity, the air manager and heater cooler. And that's why we're, from a technology standpoint, think that when we launch those products, Essence is just going to perform even better in terms of its technical abilities.

Mike Pollark Analyst — Wolf Research, LLC

Helpful. One follow-up, and then we can move to epilepsy. I think the oxygen market is just an interesting one, two-parter. Do you still have any surprise that your competitors haven't responded in the way that you seem to be responding? And any evidence that that could change or no, this is Levinova's market to win, and that's question one. And then two is just this... You know, sustaining a double-digit increase in output, that's volume, and there's still positive price. I just want to confirm that as an expectation as you roll into 27.

So maybe start with the end of the question. Absolutely. So it's volume and price, and I think one of the Levanova's strong capabilities is strategic pricing, and so absolutely price is going to play a role in that. Regarding the market itself. I think we were all surprised with the elevation of procedure growth, and that caught us by surprise a few years ago. This is also the market where scale matters, because it's... High capital intensity. It's very high volume. It's relatively low value in terms of unit sales. And then so, and then that type of market scale matters. So now that we have approximately 40% market share, it just makes us more competitive purely from scale point of view. And then, you know, we saw some of the competitors exit for that exact reason that, you know, getting, for example, had about 5% market share. They exited the market, and that created another kind of opportunity for us to... To gain share, but we have a relatively high level of confidence that the momentum we gained over the last couple of years due to those factors and the fact that scale matters that that momentum will carry into the future.

Mike Pollark Analyst — Wolf Research, LLC

Good. Let's shift gears to epilepsy. I'm not going to start on pricing. I want to ask about U.S. NPI, new patient implant trends, kind of 1Q, 2Q, 3Q. The environment is different because the provider reimbursement is up, and so the case is more attractive than it was a year ago. Core VNS, you're investing in clinical evidence, and that demonstrates good outcomes, and now the word is getting out, and maybe just commercial excellence. And it's like, it feels... Like, a better setup. I would love you to just comment on, you know, quarterly progression this year, and what are you seeing out of NPI? What are those growth rates in the United States?

So maybe I'll start, and then I'll ask Ahmed to comment a little bit more on the clinical data, because I think it is transformative data. But if I step back on our epilepsy business, there are two major tailwinds that happened this year. Number one is more on the economic front, and that is for both new implants and replacement implants. The reimbursement went up by approximately 50%. And I have never seen this in my 30 years in the tech industry, that on a mature product, there is such significant improvement in reimbursement, and that gave hospitals and other providers opportunities to kind of make this procedure more profitable for them and more economically viable. And with that trend, what we're starting to see also is there were a number of accounts that closed due to the economic unsustainability that now are opening back. And so that is one big trend that we're seeing. The other big trend is due to the clinical data. We are seeing that VNS is starting to play a more advanced role, a larger role in the clinical practices of epileptologists. And so that's another trend that we're seeing. And then from the price point of view, we are now able to. We renegotiate and not give as much volume discount. So it kind of gave us the price uplift. So, and if I look at progression, I mean, you can see that the business has grown double digit in the last quarter. We are following very closely what are the trends, kind of, we want to get a few quarters behind us to be able to then kind of shape the guide moving forward. But what we clearly see is When those two things happened, clinical data came out and the reimbursement increased, we first saw the uplift in price almost immediately. And then gradually throughout the year, we're starting to see uplift in volume. And I think that isn't kind of what we should continue to expect. But ultimately, our goal is that we can kind of normalize price increases to our annual increases. And then but see kind of increased volume year after year, quarter after quarter. But a lot of that will be driven by. The acceptance of the clinical data that we've published recently, and Amit, maybe you can comment.

Ahmet Tezel Other

One of the challenges we had in the past was the FDA trial for VNS was done in early 2000, so the clinical data on label is pretty old. And at that time, the technology was in a very different state in terms of its features. For example, it didn't have auto-stimulation where when the device detects you're having a seizure, it kicks in. So the data was old, and the effectiveness data wasn't representative around what it can do today. So that created challenges because it's a class three device, so it's heavily regulated. You can't just promote from a paper here, a paper there. So we knew the performance was better, but we didn't have enough evidence to be able to promote with it. So the core data, which is 800-plus patients, 60 sites, 16 countries, the breath is strong that now we can promote with it. And the performance of the device in terms of seizure reduction is... Extremely high. It's actually almost twice as high than the original PMA data in the high 70s for seizure reduction. And 50% of the patients were seizure-free from the highest risk seizures. So that's why it's extremely exciting because now it's no longer just a less invasive option. It's the less invasive option with equal effectiveness in terms of seizure reduction.

Mike Pollark Analyst — Wolf Research, LLC

On reimbursement, just new tech APC 1580 confirmed again for 27, so that's good news. The path to level six, the visibility into it, where does that stand today?

Ahmet Tezel Other

Yeah. So, I mean, we're happy to hear that the new tech APC is continuing. We will continue to work for a level six, but now the reimbursement is stable with the new tech APC, so we're very happy about that. We will continue to work with CMS in terms of upgrading it to level six for a more permanent solution, but where it stands today, we're very happy with it because the reimbursement is now stable and at that high level.

Mike Pollark Analyst — Wolf Research, LLC

Maybe on the innovation front in epilepsy, the next-gen IPG, I think 27 at some point. What is it? Why is it different? And, you know, when is it coming? How might it be rolled out?

Ahmet Tezel Other

Yeah, I mean, we're confident it will be 27. It solves a fundamental workflow challenge for these patients. Today, when you have an implant, the only way a physician can interact with that implant is you have to be in the physician's office, and there's a third-party device that connects with the device. So if you're a new patient, you have to do that eight to ten times first year because you need to get your titration up. And post first year, you need to go to the physician's office once or twice a year. So these patients are either pediatric, and if they're adults, they don't usually have a driving license. So it's two people, the caregiver and the patient. And the average travel is about 40 miles to these centers, and in rural areas, it could be up to 150 miles. So with the new technology, we essentially have a brand new power generator or device that communicates through Bluetooth with the patient's phone. And now the entire connection with the device for the physician can happen remotely. So the physician will be able to sit in front of their computer and adjust the device remotely. It has another benefit. So that completely eliminates that eight to 10 times first year and one to two times a year. It's the same coverage in terms of reimbursement for the physician. So there's no change there. The other advantage is that now a physician can see how the product is performing. So he or she can log in and say, well, last month, your auto stimulation kicked in 20 times. Let's adjust your dose. Today, they can't do that. Today, it's all relying on, you know, did you have more seizures? Did you have less seizures? And you need to be in the office. So it fundamentally improves the workflow. And we think in the long run, it's going to improve outcomes, too, because adjustments are just going to be more efficient.

Mike Pollark Analyst — Wolf Research, LLC

Can you use this to drive? The replacement cycle? I mean, it feels like something where there's a whole... Base of patients, this is a major improvement. Call them today, early swap, or is that other part?

Ahmet Tezel Other

Yeah, I mean, that will be between the physician and the patient. It is still a surgery, so they have to say, okay, the risk benefit. But it will work backwards. So any patient that has any neuromodulation implant from Livanova would be able to be upgraded with this new device when they have their replacement.

Mike Pollark Analyst — Wolf Research, LLC

Does this also, is there a component of this hardware that creates? Just firmware upgrades in the future?

Ahmet Tezel Other

100%. So we have now a Livanova cloud system, which we're very proud of. We view ourselves as very front end of med tech in terms of cloud AI capabilities. We can now remotely upgrade all devices for epilepsy, sleep apnea, and we are now also upgrading Essence to be able to utilize the cloud. So, everything, it will happen through Livanova Cloud.

Mike Pollark Analyst — Wolf Research, LLC

All right, last one on epilepsy. Good discussion thus far. On the risk side, you know, I... Drugs are an option for patients with seizure disorders, and polypharmacy, I think, is very common, and there is innovation. There's always been innovation, new drugs launching, and I think there seems to be a little bit of a pipeline ahead. So, you know, what are you doing today to prepare for, you know, the VNS franchise for perhaps another round of, not transformative, but new drugs to try? And I think we've learned that patients are always interested in trying the next thing. So how are you preparing for that to the extent there's a cycle the next few years?

Ahmet Tezel Other

Everyone? Um, so, yes, so, um, In epilepsy, if you have epilepsy, two-thirds of the patients respond to drugs, one-third does not respond to a drug, and they're called drug-resistant epilepsy. If you look at the drug world, the focus is on that first two-thirds, and it's usually not improve effectiveness of the drug, but it's usually innovation is to reduce the side effects of these drugs, Because the way these drugs work is that they reduce brain activity. And obviously, when you reduce brain activity, it comes with a consequence. So we don't see anything in the pipeline, including the 2028 launch with a drug, Xenon, a drug that fundamentally changes that paradigm that you have one third of patients that continue to become drug resistant. And unfortunately, the way it works is that if you don't respond to the first two drugs that your physician prescribes you, after the third, fourth, fifth drug, you're down to 1%, 2%, 3% responder rate. So usually, if you are a drug-resistant epilepsy patient, you stay as a drug-resistant epilepsy patient, and that's the area that we... We serve.

Maybe just to add one thing is, it's not either drugs or VNS. Normally, patients that are VNS also have complementary drug therapy, so they're managed with both neuromodulation and medication.

Mike Pollark Analyst — Wolf Research, LLC

VNS is adjunct today.

It enables you to reduce your drug dosage, too.

Mike Pollark Analyst — Wolf Research, LLC

Good. Let's move to sleep apnea. I think I get it. The device looks very competitive, and PolySync furthers that claim. I guess what I want to say is that I'm impressed to slightly surprise you sound. Very optimistic about this opportunity and are moving forward for it. So I'm not going to ask for a reminder on why you think it's competitive. I think I'm there. I think it's the path. And making that $200 million to $400 million revenue realization in 2030 come to fruition is going to be a lot of hard work. So what is the path? We have a PMA. We need to supplement the timing of that. Next year sounds really like the LMR year and 28 full launch. Have I mischaracterized anything on timing and maybe comment on the level of confidence in the...

Ahmet Tezel Other

I mean, I'll start with that part of the question, and Vlad can answer the first part, too. So, yes, we are very confident that the LMR will happen in 2027.

Mike Pollark Analyst — Wolf Research, LLC

So, on the supplement, is it just the MRI, or is there another component, MRI labeling, or is there another supplement?

Ahmet Tezel Other

No, it's a different IPG. So, we conducted the trial with a power generator that was designed years ago. This one is Bluetooth connected. So it has all the digital capabilities like the epilepsy and still connected to the Livanova cloud. So I would describe it as MRI compatibility is very important, but equally important, if not more, is the digital capabilities. Remote programming, for example, will be available with this device.

Mike Pollark Analyst — Wolf Research, LLC

So just remind me on the timeline that was communicated last week.

Ahmet Tezel Other

Yeah, so what we said is... Between the end of this year and first half of next year, we will submit the PMA supplement. And, you know, that was a time we communicated last quarter. So now we have three months more of data and time. So our confidence is now significantly higher on where we are. So we're very confident that those timelines will happen and LMR will be in 2027.

Mike Pollark Analyst — Wolf Research, LLC

Is it the next, before the end of this year, or is it the first half?

Ahmet Tezel Other

There's a wide range. If I see that, I get in trouble, so I won't.

Mike Pollark Analyst — Wolf Research, LLC

I guess, you know, the market is large. I think it's really only been one company to this point. That market has fallen on growth challenges this year. I think one of the active debates is, is it saturation or is it the coding confusion? I guess, comment briefly, if you don't mind, on your confidence and how you think. Things for the category overall evolve in 27, 28, 29, 2030, especially as you become a participant in the market.

So we have high level of confidence in this market, and I would say there are several factors at play to it. You know, the first one always starts with unmet patient need, and, you know, you look at the, you know, still about close to a million patients. Get off CPAP every year, just in the United States, and the penetration within patient group with neuromodulation treatment is still below 5%. So that just for the market, for the technology itself, it creates a significant opportunity to drive improved penetration. Number two is... When we enter the market, we don't have counter-indication for complete concentric collapse, and about a third of the patient population in that group have complete concentric collapse that today do not have an option to treat with neuromodulation. So when we enter the market, the market expands automatically to those patients with complete concentric collapse. And then the third piece is... We believe that our clinical data gives us a strong right to win. So if you think about it, so our technology works on 100% of patients versus excluding complete concentric collapse. And within that larger group, we have 85% responder rate, which means instead of one out of three patients gets a surgery today and doesn't have response. With our technology, it's one out of seven patients that get a surgery and doesn't get response. So that's a very, and that's how clinicians talk to us about it. That's a very significant clinical benefit to patients, you know. So, believe in the market because of high unmet need, additional market driven by complete concentric collapse patients, and our clinical data that gives us competitiveness in this space.

Mike Pollark Analyst — Wolf Research, LLC

We have... One minute, I have two topics, would love brief comment on margin profitability. It's expanding this year. 2027, you know, you can imagine maybe flattish because you have to invest to fund sleep. Is that just a, I know you don't have formal guidance, but you do have an LRP. Is that a reasonable way to start? Could margin expand this year?

So we'll obviously guide after the next quarter, but at this point, I will just take you back to what we've guided to during the Investor Day, where we said 25 to 28, we will maintain margin above 20%. We will expand margin in our core business and reinvest it in sleep apnea. We are doing those investments in very disciplined ways. So we prove success, invest, prove success, invest. And then post-2028, OSA starts scaling and starts contributing significantly to overall margin. And so we expect by 2030, OSA margin itself will be north of 25%. And then, yeah, we will guide more precisely after the next quarter.

Mike Pollark Analyst — Wolf Research, LLC

Depression, briefly the update, what's the next action item?

Ahmet Tezel Other

So CMS was, they wanted to know if the durability of the therapy is there. In neuromodulation, it is expected the longer use in neuromodulation device, almost in all diseases, the benefits improve. But they... I mean, scientifically, rightfully wanted to know if it's there. So the three-year data was available to us in May from the recovery trial. So we prepared that, analyzed that. And another requirement of CMS is that you cannot utilize data in a submission unless it's... In the public domain. So peer-reviewed article or at least minimum in public domain. So we did that and submitted it to them. So that was, you know, early fall. We have not heard back, but our expectation based on the strength of the three-year data, which is publicly available, is that that should answer their question around is this therapy durable or not.

Mike Pollark Analyst — Wolf Research, LLC

From there, they will respond eventually.

Ahmet Tezel Other

Yeah, I mean, they will never tell you, it's similar to FDA, they will never tell you definitively, it's done, now go here. But they might say something like, we have no further questions. Or they could come with new questions about the clinical data. That would be our kind of cue, okay, should we go to formal or not?

Mike Pollark Analyst — Wolf Research, LLC

Good. Vlad and Matt, thanks for being here. I appreciate the conversation. Thank you, Mike. Thank you, everybody. Thank you.

Analyst Q&A · 1 question
Full-screen source Call document